Chinese Journal of Dermatology ›› 2020, Vol. 53 ›› Issue (5): 317-318.doi: 10.35541/cjd.20200283

• Expert Commentary •     Next Articles

Guidance on the use of biologic agents in psoriatic patients during COVID-19 outbreak

Wang Gang1, Gu Heng2, Zheng Min3, Zhao Yi4, Gu Jun5, Jin Hongzhong6, Liu Xiaoming7, Shi Yuling8, Sun Qing9   

  1. 1Department of Dermatology, Xijing Hospital, The Fourth Military Medical University, Xi′an 710032, China;  2Hospital for Skin Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China; 3Department of Dermatology, The Second Affiliated Hospital of Zhejiang University School of Medcine, Hangzhou 310009, China;  4Department of Dermatology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China;  5Department of Dermatology, Tenth People′s Hospital of Tongji University, Shanghai 200000, China; 6Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China;  7Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen 518053, China;  8Shanghai Skin Diseases Hospital, Shanghai 200443, China;  9Department of Dermatology, Qilu Hospital of Shandong University, Jinan 250012, China
  • Received:2020-03-23 Revised:2020-03-30 Online:2020-05-15 Published:2020-04-30
  • Contact: Wang Gang; Gu Heng;

Abstract: 【Abstract】 The COVID-19 outbreak may have a certain impact on the use of biologics in psoriatic patients, in the way that immunosuppressive effects of biologics may potentially alter the susceptibility of patients to the virus, deteriorate the condition of infected patients or even change the prognosis of infection. According to currently available recommendations from international psoriasis academic organizations and specialists, as well as specific situation in China, the authors provide some guidance on the use of biologics for psoriatic patients undergoing or planning to undergo treatment with biologics, those with low or high risk of infection, and for those with or without COVID-19 infection, so as to provide references for clinical practice.

Key words: COVID-19, SARS-CoV-2, Psoriasis, Biologic agents